SynthesisJBRA assisted reproduction2025
Utility of GnRH Agonists before embryo transfer in women with adenomyosis: Systematic review and meta-analysis.
Synthesis in JBRA assisted reproduction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis aimed to evaluate the benefit of GnRH agonist (GnRHa) in reproductive outcomes among women with adenomyosis undergoing IVF. The utility of GnRHa protocols for controlled ovarian stimulation (COS) and fresh embryo transfer, and the pretreatment with GnRHa before frozen-thawed embryo transfer were evaluated. The search spanned studies published in MEDLINE and Embase databases up to April 2024. Eight retrospective studies were included. The use of long GnRHa and antagonist protocol before COS exhibited significantly higher implantation rate compared to ultra-long GnRHa (OR 1.1, 95% CI 0.69-1.77 and OR 1.98, 95% CI 1.04-3.75, respectively), although no significant differences were observed in clinical and live birth rates. However, antagonist compared to long GnRHa protocol before COS improved live birth rate (OR 2.59, 95% CI 1.03-6.52). Pretreatment with GnRHa before FET among women with adenomyosis did not improve reproductive outcomes. In conclusion, there is no evidence regarding benefit of long or ultra-long GnRHa protocol before COS or before FET among women with adenomyosis undergoing IVF. In fact, the use of long GnRHa seem to worsen reproductive outcomes compared to antagonist protocols. Prospective trials are needed to assess the potential benefit of GnRHa among women with adenomyosis seeking fertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.